NCT01532869 - A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

August 31, 2015

Conditions

Sclerosis, Systemic

Interventions

DRUG

Placebo

Subcutaneously weekly, Weeks 0-48

DRUG

tocilizumab [RoActemra/Actemra]

162 mg subcutaneously weekly, Weeks 0-48

DRUG

tocilizumab [RoActemra/Actemra]

162 mg subcutaneously weekly, Week 48-96

Trial Locations (50)

10021

New York

10177

Berlin

11042

Lake Success

14033

Caen

15261

Pittsburgh

19131

Philadelphia

20007

Washington D.C.

21224

Baltimore

22763

Hamburg

29425

Charleston

31000

Toulouse

33075

Bordeaux

43614

Toledo

44122

San Diego

44195

Cleveland

44791

Bochum

50937

Cologne

59037

Lille

60528

Frankfurt

60611

Chicago

61231

Bad Nauheim

67091

Strasbourg

72076

Tübingen

73103

Oklahoma City

75679

Paris

76530

Baden-Baden

77030

Houston

84132

Salt Lake City

89081

Ulm

90025

Los Angeles

91054

Erlangen

98104

Seattle

94305-5317

Stanford

06030

Farmington

02118

Boston

48109-0934

Ann Arbor

08903

New Brunswick

N6A 4V2

London

M5G 1X5

Toronto

H3T 1E2

Montreal

01067

Dresden

WS11 5XY

Cannock

DD1 9SY

Dundee

EH4 2XU

Edinburgh

LS7 4SA

Leeds

L9 7AL

Liverpool

NW3 2QG

London

TS4 3BW

Middlesbrough

NE7 7DN

Newcastle upon Tyne

RM7 0AG

Romford

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY